News
2d
TipRanks on MSNInstil Bio announces ImmuneOnco presentation of ‘2510 monotherapy data
Instil Bio (TIL) announced that ImmuneOnco Biopharmaceuticals presented preliminary efficacy and safety data of ‘2510 as monotherapy in a Phase 1 ...
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. Preclinical data on VRB-103, Verdiva Bio’s once-weekly ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
-- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining ...
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results